InVariant BiobyAndrew Farnum·Just nowFrom the Shores of Lake Albert to Variant Bio’s First Clinical TrialNew coverage in Core Memory tells the origins of Variant’s first drug candidate, and the power of human genetics to discover new medicines
InVariant BiobyAndrew Farnum·Sep 28Expanding Our Target Discovery Collaboration with Boehringer Ingelheim into Cardiovascular DiseaseVariant Bio leverages AI-powered Inference platform in an expanded collaboration with Boehringer Ingelheim
InVariant BiobyAndrew Farnum·Jan 7Variant Bio Announces Partnership with Boehringer Ingelheim on New Kidney Targets Discovered with…Coinciding with our most recent pharma collaboration, we officially launched our Inference agentic AI platform and an accompanying website
InVariant BiobyAndrew Farnum·Jan 7, 2025Variant Bio Announces Multi-Year Research Partnership with Novo NordiskWe are collaborating with Novo Nordisk to discover novel targets for the treatment of metabolic disease
InVariant BiobyAndrew Farnum·Apr 18, 2024Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis TreatmentsPress release details collaboration aimed at addressing unmet medical need in fibrotic indications
InVariant BiobyAndrew Farnum·Jan 9, 2023Taking Stock: Two Years Into Variant Bio’s Unique Benefit-Sharing ProgramA summary of the work Variant Bio has done to date to ensure short-term benefits are rolled out around the world
InVariant BiobyAndrew Farnum·Oct 26, 2022Announcing Variant Bio’s Affordable Medicines PledgeHow we are expanding our commitment to sharing the benefits of research with partner communities around the world
InVariant BiobyAndrew Farnum·Nov 12, 2021Variant Bio Finalizes Series B FinancingOur mission at Variant Bio is to develop life-saving therapies by studying the genetics of diverse populations that are outliers for…
InVariant BiobyAndrew Farnum·Nov 11, 2020Variant Bio Announces Formal Commitment to Benefit SharingHow we are breaking ground in genomics research by guaranteeing benefits for our partner communities
InVariant BiobyAndrew Farnum·Aug 12, 2020Variant Bio Finalizes Series A FinancingInvestors include Lux Capital, Alta Partners, Casdin Capital, Sahsen Ventures, and Alexandria Venture Investments